Asian Pacific Journal of Cancer Prevention · 2014 · 46 citations · 29 references
MedicineGeneticsOncologyEpigeneticsGynecologic OncologyMolecular OncologyCancer EpigeneticsEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsOvarian CancerTumor Suppressor GenesAberrant Dna MethylationCpg Island Aberrant MethylationMalignant Ovarian NeoplasmsPromoter HypermethylationPromoter MethylationTumor Suppressor Gene AlterationsTumor Suppressor Gene HypermethylationTumor Suppressor Gene Methylation
OBJECTIVE: The tumor suppressor gene, Ras-association domain family (RASSF)2A, is inactivated by promoter hypermethylation in many cancers. The current study was performed to evaluate the methylation status of RASSF2A in epithelial ovarian cancer (EOC) tissues and plasma, and correlations with gene expression and clinicopathologic characteristics. METHOD: We detected methylation of the RASSF2A gene in tissues and corresponding plasma samples from 47 EOC patients and 14 patients with benign ovarian tumors and 10 with normal ovarian tissues. The methylation status was determined by methylation-specific PCR while gene expression of mRNA was examined by RT-PCR. The EOC cell line, SKOV3, was treated with 5-aza-2'-deoxycytidine (5-aza- dC). RESULTS: RASSF2A mRNA expression was significantly low in EOC tissues. The frequency of aberrant methylation of RASSF2A was 51.1% in EOC tissues and 36.2% in corresponding plasma samples, whereas such hypermethylation was not detected in the benign ovarial tumors and normal ovarian samples. The expression of RASSF2A mRNA was significantly down-regulated or lost in the methylated group compared to the unmethylated group (p<0.05). After treatment with 5-aza-dC, RASSF2A mRNA expression was significantly restored in the Skov3 cell line. CONCLUSION: Epigenetic inactivation of RASSF2A through aberrant promoter methylation may play an important role in the pathogenesis of EOC. Methylation of the RASSF2A gene in plasma may be a valuable molecular marker for the early detection of EOC.
29
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text
Free DNA in the serum of cancer patients and the effect of therapy.
Shalom A. Leon, B Shapiro, D.M. Sklaroff et al. · PubMed · 1977 · 1.8K citations
Medicine, Immunology, Oncology +13
Stephen A. Cannistra · New England Journal of Medicine · 1993 · 293 citations
Medicine, Gynecology, Oncology +14